Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q1 2019 (← Previous) (Next →)

Filing Date: May 15, 2019

Total Value ($000): $664,251 (100.0% shares, 0.0% debt)

Holdings (11)

— ALLERGAN PLC 19.1%
Value ($000) $127,083 Shares 868,000 Est. Cost $150.71 Unrealized —
BIIB BIOGEN INC 18.7%
Value ($000) $124,018 Shares 524,658 Est. Cost $288.76 Unrealized +9.0%
IRWD IRONWOOD PHARMACEUTICALS INC. 15.4%
Value ($000) $102,045 Shares 7,542,200 Est. Cost $11.99 Unrealized -6.9%
— MEDICINES CO 15.3%
Value ($000) $101,626 Shares 3,636,000 Est. Cost $26.65 Unrealized —
INVA INNOVIVA INC 12.7%
Value ($000) $84,546 Shares 6,026,100 Est. Cost $12.95 Unrealized +25.0%
PBYI PUMA BIOTECHNOLOGY INC 8.3%
Value ($000) $54,965 Shares 1,417,000 Est. Cost $30.04 Unrealized +1.7%
— INTERCEPT PHARMACEUTICALS INC 5.4%
Value ($000) $35,795 Shares 320,000 Est. Cost $103.21 Unrealized —
— MERSANA THERAPEUTICS INC 3.0%
Value ($000) $19,725 Shares 3,750,000 Est. Cost $5.26 Unrealized —
JAZZ JAZZ PHARMACEUTICALS INC 2.2%
Value ($000) $14,295 Shares 100,000 Est. Cost $130.43 Unrealized 0.0%
ABBV ABBVIE INC 0.0%
Value ($000) $80 Shares 1,000 Est. Cost $38.85 Unrealized +57.1%
— MIRATI THERAPEUTICS INC 0.0%
Value ($000) $73 Shares 1,000 Est. Cost $42.00 Unrealized —